A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: A risk factor analysis of outcomes for patients in remission at transplantation

Blood

Volumn 112, Issue 9, 2008, Pages 3574-3581

  Ciceri, Fabio ^a   Labopin, Myriam ^b   Aversa, Franco ^c   Rowe, Jakob M ^d   Bunjes, Donald ^e   Lewalle, Philippe ^f   Nagler, Arnon ^g   Di Bartolomeo, Paolo ^h   Lacerda, João F ⁱ   Stangheilini, Maria Teresa Lupo ^a   Polge, Emmanuelle ^b   Frassoni, Francesco ^j   Martelli, Massimo F ^c   Rocha, Vanderson ^b,k  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF PERUGIA   (Italy)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g SHEBA MEDICAL CENTER   (Israel)

^h Ospedale Civile di Pescara   (Italy)

ⁱ UNIVERSITY OF LISBON   (Portugal)

^j San Martino Polyclinic of Genova   (Italy)

^k SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY; MORPHOLINE DERIVATIVE; RE 102;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; DONOR; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; EUROPE; FEMALE; FOLLOW UP; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION; CLINICAL TRIAL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HAPLOTYPE; IMMUNOLOGY; LYMPHATIC LEUKEMIA; LYMPHOCYTE TRANSFUSION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; REGISTER; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MORPHOLINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REGISTRIES; RISK FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 55749091291     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-140095     Document Type: Article

References (22)

1. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2006;37:439-449.
2. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical cord blood or bone marrow from unrelated donors in adult with leukemia. N Engl J Med. 2004;351:2276-2285.
3. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265-2275.
4. Gratwohl A, Baldomero H, Frauendorfer K, et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant. 2007;39:71-87.
5. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell depleted haploidentical three loci incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony stimulating factor mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948-3955.
6. Aversa F, Tabilio A, Velardi A, et al. Treatment of high risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339:1186-1193.
7. Aversa F, Terenzi A, Tabilio A, et al. Full-haplotype mismatched hematopoietic stem cell transplantation: a phase II study in patients with acute leukemia at high risk or relapse. J Clin Oncol. 2005;23: 3447-3454.
8. Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J Haematol. 2006;135:423-437.
9. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-vs-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
10. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-vs-host syndrome in man: a longterm clinico-pathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
11. Gooley TA, Leisenring W, Crowley JA, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:665-706.
12. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
13. Gorin NC, Labopin M, Rocha V, et al. Marrow vs peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood. 2003;102:3043-3051.
14. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106:4397-4406.
15. Andre-Schmutz I, Dal Cortivo L, Fischer A, Cavazzana-Calvo M. Improving immune reconstitution while preventing GVHD in allogeneic stem cell transplantation. Cytotherapy. 2005;7:102-108.
16. Gregori S, Bacchetta R, Hauben E, Battaglia M, Roncarolo MG. Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. Curr Opin Hematol. 2005;12:451-456.
17. Bethge WA, Haegele M, Faul C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol. 2006;34:1746-1752.
18. Maccario R, Moretta A, Cometa A, et al. Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant. 2005;11:1031-1032.
19. Ciceri F, Bonini C, Gallo Stampino C, Bordignon C. Modulation of graft-vs-host disease by suicidegene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy. 2005;7:144-149.
20. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006; 108:1092-1099.
21. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91:78-83.
22. van Rood JJ, Loberiza FR Jr, Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-vs-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002;99: 1572-1577.